

COMPUGEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(U.S. dollars in thousands, except for share and per-share amounts)

	Three Months Ended	
	<u>March 31</u>	
	<u>2013</u>	<u>2012</u>
	<u>Unaudited</u>	<u>Unaudited</u>
Revenues	162	-
Cost of Revenues	150	-
Gross profit	12	-
Operating expenses		
Research and development expenses, net	2,739	2,100
Marketing and business development expenses	195	195
General and administrative expenses	1,042	824
Total operating expenses *	3,976	3,119
Operating loss	(3,964)	(3,119)
Financial income (expenses), net **	590	(1,000)
Net loss	(3,374)	(4,119)
Basic and diluted net loss per ordinary share	(0.09)	(0.12)
Weighted average number of ordinary shares outstanding	37,283,753	35,291,165

* Includes non-cash expenses related to stock based compensation

** Includes non-cash expenses related to the Baize research and development funding arrangements.

COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars, in thousands)

	March 31,	December 31,
	<u>2012</u>	<u>2011</u>
	<u>Unaudited</u>	<u>Audited</u>
ASSETS		
Current assets		
Cash, cash equivalents and short-term bank deposits	24,649	19,589
Restricted cash	98	96
Investment in Evogene	4,858	5,196
Other accounts receivable and prepaid expenses	709	690
Total current assets	30,314	25,571
Non-current investments		
Long-term lease deposits	60	59
Severance pay fund	1,822	1,728
Total non-current investments	1,882	1,787
Long-term prepaid expenses	251	301
Property and equipment, net	1,184	1,250
Total assets	33,631	28,909
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Other accounts payable, accrued expenses and trade payables	1,773	1,384
Total current liabilities	1,773	1,384
Non-current liabilities		
Research and development funding arrangements and others	7,972	7,872
Accrued severance pay	2,131	1,981
Total non-current liabilities	10,103	9,853
Total shareholders' equity	21,755	17,672
Total liabilities and shareholders' equity	33,631	28,909